Although it has been speculated that estrogen therapy may promote changes in breast tissue that could lead to cancer, no information exists as to differences in breast tissue for women who do and do not take hormone replacement (HRT) therapy. This study seeks to determine if there are differences in the tissue of women taking HRT in contrast to those who do not and if these differences are apparent in cases of breast cancer, cellular atypia, fibrocystic (FCD) disease and normal breasts. A total of 327 non-pregnant, nonlactating, pre-menopausal women were enrolled in the study, including 139 women who were actively taking HRT and 188 women who never had taken HRT. Using breast enhanced scintigraphy test (BEST) imaging, differentiation of breast tissue was determined. The groups were then analyzed to determine the effect of hormone therapy within each category of breast tissue. Differentiation between normal, FCD, cellular atypia, and breast cancer represent statistically significant differences (p.001) in metabolic activity and vascularity as demonstrated by differences in both average count activity (ACA) and maximal count activity (MCA). The distinction between cellular atypia and infiltrating breast cancer was statistically (p.05) different when looking at the maximal activity. Normal breast tissue and breasts with FCD appear more homogenous with no statistical differences in variability in breast tissue. Tissue variability is statistically greater when localized processes, such as cellular atypia and breast cancer, are present. Differentiation of cellular metabolic activity in breast tissue can be statistically determined when looking at the average and maximal metabolic activity. The final distinction between cellular atypia and cancer occurs when a focal region of breast tissue becomes metabolically more active than the surrounding breast tissue as shown by statistical increases in MCA. These findings are confirmed by the increased metabolic variability seen in regions of cellular atypia and cancer compared with the homogenous metabolic activity present in normal and fibrocystic breasts.
References
1.
1. Romero L, Khalkhali I, Vargas HI. The role of nuclear medicine in breast cancer detection: a focus on technetium-99 sestamibi scintimammography . Curr Oncol Rep. 2003;5: 58-62 .
2.
2. Scopinaro F, Varvarigou A, Ussof W, et al. Breast cancer takes up 99mTc bombesin. A preliminary report . Tumori. 2002;88: S25-S28 .
3.
3. Vanoli C, Antronaco R, Giovanella L, Ceriani L, Sessa F, Fugazzola C. 99mTc-MIBI characterization of breast microcalcifications. Correlations with scintigraphic and histopathologic findings . Radiol Med (Torino). 1999;98: 19-25 .
4.
4. Caner B, Beller GA. Are technetium-99m-labelled myocardial perfusion agents adequate for detection of myocardial viability? Clin Cardiol. 1998;21: 235-242 .
5.
5. Hetrakkul N, Civelek AC, Stagg CA, Udelsman R. In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondria . Surgery. 2001;130: 1011-1018 .
6.
6. Yapar Z, Kibar M, Sukan A, Paydas S, Zeren H, Inal M. Coincidental visualization of an atypical bronchial carcinoid on Tc-99m-sestamibi scan in Kallmann's syndrome . Ann Nucl Med. 2002;16: 61-65 .
7.
7. Mankoff DA, Dunnwald LK, Gralow JR, et al. Tc-99m-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow . Nucl Med Biol. 2002;29: 719-727 .
8.
8. Kim R, Osaki A, Hirai T, Toge T. Utility of technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer . Breast Cancer. 2002;9: 240-247 .
9.
9. Re C, Jin S, Zhou Q, Zhu H, Wang H, Liang C. Clinical significance of 99mTc-MIBI breast imaging in the diagnosis of early breast cancer . Asian J Surg. 2002;25: 126-129 .
10.
10. Chen YS, Wang WH, Chan T, Sun SS, Kao A. A review of the cost-effectiveness of Tc-99m sestamibi scintimammography in diagnosis of breast cancer in Taiwanese women with indeterminate mammography dense breast . Surg Oncol. 2002;11: 151-155 .
11.
11. Fleming RM, Dooley WC, Boyd LB, Kubovy C. Breast enhanced scintigraphy testing (BEST)-increased accuracy in detecting breast cancer accomplished by combining breast and cardiac imaging . Paper presented at: 48th Annual Scientific Session of the Society of Nuclear Medicine; June 27, 2001; Toronto, Ontario, Canada.
12.
12. Fleming RM. Mitochondrial uptake of sestamibi distinguishes between normal, inflammatory breast changes, pre-cancers and infiltrating breast cancer . Int Cancer Ther. 2002;1: 229-237 .
13.
13. Fleming RM, Dooley WC. Breast enhanced scintigraphy testing (BEST) distinguishes between normal, inflammatory breast changes and breast cancer. A prospective analysis and comparison with mammography . Int Cancer Ther. 2002;1: 238-245 .
14.
14. Snedecor GW, Cochran WG. Statistical Methods. 6th ed. Ames: The Iowa State University Press ; 1967.
15.
15. Freund A, Chauveau C, Brouillet JP, et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells . Oncogene.2003; 22: 445-450 .
16.
16. Fleming RM, Monte T. Stop Inflammation Now! New York: G. P. Putnam ; 2003.
